Alector (ALEC) recently reported that its experimental therapy latozinemab did not meet the main efficacy goal in a late-stage trial for frontotemporal dementia. As a result, multiple follow-up ...

Emma Heming Willis shares caregiving lessons and family strength during Bruce Willis' frontotemporal dementia battle ...

Alector Inc. cuts its workforce by nearly 50% following the failure of its dementia drug trial, signalling challenges in the ...

Wendy is preparing to take the stand at her deposition hearing. The post Wendy Williams Preparing for Court With ‘Intense ...

EXCLUSIVE: Wendy Williams' Courtroom Comeback! Dementia-hit Television Host Having 'Intense Training Sessions' to Prepare for Deposition in Lawsuit Over Documentary Warrior Wendy Williams is plotting ...

A research registry tracking data on a particular form of dementia will be created under a new law sponsored by state Sen.

The firm's monoclonal antibody latozinemab did not slow disease progression in patients with dementia due to progranulin gene mutations.

Village Caregiving reports that frontotemporal dementia is a progressive brain disease affecting behavior, speech, and memory ...

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; ...

Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with ...

A new law in New York will create a statewide registry that will help track and raise awareness of frontotemporal ...